Revelation Biosciences (REVB) Corporate presentation summary

Program pipeline and market opportunity

• Lead programs target acute kidney injury (AKI) and chronic kidney disease (CKD), both with significant unmet needs and large market potential, estimated at $5.5 billion for AKI and $9.2 billion for CKD.

• Gemini, a proprietary TLR-4 agonist platform, is the basis for current and future programs, with potential applications in neurodegenerative, hepatic, cardiovascular, connective tissue, and hyperinflammatory diseases.

• AKI affects about 50% of ICU patients, with severe cases requiring dialysis and high mortality rates; CKD impacts 10% of the global population and is often a consequence of AKI.

Clinical development and data

• A Phase 2/3 pivotal study for Gemini in severe AKI is set to begin, using an adaptive design agreed upon with the FDA, targeting approximately 300 patients.

• Preclinical and clinical data show Gemini normalizes inflammatory responses, reduces pro-inflammatory cytokines, and restores immunocompetence without immunosuppression.

• In animal models, Gemini significantly reduced renal fibrosis, improved organ function, and decreased tissue damage and inflammation.

• Human studies confirm cytokine and cellular upregulation consistent with animal data, supporting translational potential.

Financial position and management

• Cash balance as of December 2025 was $10.7 million, with $7.3 million raised in January 2026; cash runway extends into Q1 2027, sufficient to open enrollment for the pivotal study.

• Management team has extensive experience in drug development, regulatory approvals, commercialization, and has raised over $1 billion in prior financings.